摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-furyl)-2,5,6-trichloro-1-(2,3-O-isopropylidene-5-O-methoxymethyl-β-D-ribofuranosyl)indole | 801300-34-5

中文名称
——
中文别名
——
英文名称
3-(2-furyl)-2,5,6-trichloro-1-(2,3-O-isopropylidene-5-O-methoxymethyl-β-D-ribofuranosyl)indole
英文别名
2,5,6-trichloro-3-(2-furyl)-1-(2,3-O-isopropylidene-5-O-methoxymethyl-β-D-ribofuranosyl)indole;1-[(3aR,4R,6R,6aR)-6-(methoxymethoxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-2,5,6-trichloro-3-(furan-2-yl)indole
3-(2-furyl)-2,5,6-trichloro-1-(2,3-O-isopropylidene-5-O-methoxymethyl-β-D-ribofuranosyl)indole化学式
CAS
801300-34-5
化学式
C22H22Cl3NO6
mdl
——
分子量
502.779
InChiKey
QKKNDXLWZZYRSA-XLBJILASSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    32
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    64.2
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(2-furyl)-2,5,6-trichloro-1-(2,3-O-isopropylidene-5-O-methoxymethyl-β-D-ribofuranosyl)indole盐酸 作用下, 以 甲醇 为溶剂, 反应 0.75h, 以65%的产率得到2,5,6-trichloro-3-(2-furyl)-1-(β-D-ribofuranosyl)indole
    参考文献:
    名称:
    某些3取代的2,5,6-三氯吲哚核苷的设计,合成和抗病毒活性。
    摘要:
    已经合成了一系列三氯化吲哚核苷,并测试了其对人巨细胞病毒(HCMV)和1型单纯疱疹病毒(HSV-1)的活性以及细胞毒性。设计了先前报道的在杂环的3位上的2,5,6-三氯-1-(β-d-核呋喃呋喃糖基)吲哚的修饰部分是为了测试我们的假设,即在该位置需要氢键键合才能具有抗病毒活性。使用3-位的亲电加成或通过合成修饰的吲哚杂环,然后进行糖基化和糖的修饰来合成类似物。在3位的修饰中,只有那些具有氢键接受特性的类似物才具有抗HCMV的活性(例如3-甲酰基-2,5,6-三氯-1-(β-D-呋喃呋喃糖基)吲哚,FTCRI ,IC50 = 0.23 microM)。反过来,在3位上具有非氢键取代基的类似物(例如3-甲基-2,5,6-三氯-1-(β-D-核呋喃糖基)吲哚)的活性(IC50 = 32 microM)比具有必要的氢键能力的那些。获得了FTCRI的5'-O-酰基类似物作为中间体,并且发现它也是HCMV的有效抑制剂(IC50
    DOI:
    10.1021/jm0400146
  • 作为产物:
    参考文献:
    名称:
    某些3取代的2,5,6-三氯吲哚核苷的设计,合成和抗病毒活性。
    摘要:
    已经合成了一系列三氯化吲哚核苷,并测试了其对人巨细胞病毒(HCMV)和1型单纯疱疹病毒(HSV-1)的活性以及细胞毒性。设计了先前报道的在杂环的3位上的2,5,6-三氯-1-(β-d-核呋喃呋喃糖基)吲哚的修饰部分是为了测试我们的假设,即在该位置需要氢键键合才能具有抗病毒活性。使用3-位的亲电加成或通过合成修饰的吲哚杂环,然后进行糖基化和糖的修饰来合成类似物。在3位的修饰中,只有那些具有氢键接受特性的类似物才具有抗HCMV的活性(例如3-甲酰基-2,5,6-三氯-1-(β-D-呋喃呋喃糖基)吲哚,FTCRI ,IC50 = 0.23 microM)。反过来,在3位上具有非氢键取代基的类似物(例如3-甲基-2,5,6-三氯-1-(β-D-核呋喃糖基)吲哚)的活性(IC50 = 32 microM)比具有必要的氢键能力的那些。获得了FTCRI的5'-O-酰基类似物作为中间体,并且发现它也是HCMV的有效抑制剂(IC50
    DOI:
    10.1021/jm0400146
点击查看最新优质反应信息

文献信息

  • [EN] INDOLE ANTIVIRAL COMPOSITIONS AND METHODS<br/>[FR] COMPOSITIONS ANTIVIRALES A BASE D'INDOLE ET PROCEDES CORRESPONDANTS
    申请人:UNIV MICHIGAN
    公开号:WO2005034943A1
    公开(公告)日:2005-04-21
    The present invention provides novel chemical compounds and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases.
    本发明提供了新颖的化合物和它们的使用方法。具体来说,本发明提供了吲哚衍生物(例如如公式(I)所示)和相关化合物,以及使用吲哚衍生物和相关化合物作为治疗剂治疗多种疾病的方法,包括与病毒感染和心血管疾病相关的疾病。
  • Indole antiviral compositions and methods
    申请人:Townsend B. Leroy
    公开号:US20050143329A1
    公开(公告)日:2005-06-30
    The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases.
    本发明提供了新的化合物和其使用方法。特别地,本发明提供吲哚衍生物(例如如式(I)所示)和相关化合物以及使用吲哚衍生物和相关化合物作为治疗剂治疗多种疾病的方法,包括与病毒感染和心血管疾病有关的疾病。
  • Indole Antiviral Compositions And Methods
    申请人:Townsend Leroy B.
    公开号:US20090281052A1
    公开(公告)日:2009-11-12
    The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases.
    本发明提供了新型化合物及其使用方法。具体来说,本发明提供吲哚衍生物(例如如式(I)所示)和相关化合物,以及使用吲哚衍生物和相关化合物作为治疗剂治疗多种疾病的方法,包括与病毒感染和心血管疾病相关的疾病。
  • US7419963B2
    申请人:——
    公开号:US7419963B2
    公开(公告)日:2008-09-02
  • US7625871B2
    申请人:——
    公开号:US7625871B2
    公开(公告)日:2009-12-01
查看更多

同类化合物

3-formyl-2-methoxy-5,6-dichloro-1-(β-D-ribofuranosyl)indole 3-formyl-2-pyrrolidino-5,6-dichloro-1-(β-D-ribofuranosyl)indole 3-formyl-2-dimethylamino-5,6-dichloro-1-(β-D-ribofuranosyl)indole (2R,3S,4R)-2-Hydroxymethyl-5-(5-nitro-indol-1-yl)-tetrahydro-furan-3,4-diol 4,6-bis(furan-2-yl)-9-β-D-ribofuranosyl-9H-pyrimido[4,5-b]indole 6-chloro-4-(thiophen-2-yl)-9-β-D-ribofuranosyl-9H-pyrimido[4,5-b]indole 4-((furan-2-yl)-6-(furan-3-yl)-9-β-D-ribofuranosyl)-9H-pyrimido[4,5-b]indole 4-(benzofuran-2-yl)-6-chloro-9-β-D-ribofuranosyl-9H-pyrimido[4,5-b]indole 6-chloro-4-(thiophen-3-yl)-9-β-D-ribofuranosyl-9H-pyrimido[4,5-b]indole 4-((furan-2-yl)-6-phenyl-9-β-D-ribofuranosyl)-9H-pyrimido[4,5-b]indole 6-chloro-4-phenyl-β-D-ribofuranosyl-9H-pyrimido[4,5-b]indole 6-chloro-4-(furan-2-yl)-9-b-D-ribofuranosyl-9H-pyrimido[4,5-b]indole 6-chloro-4-(furan-3-yl)-9-b-D-ribofuranosyl-9H-pyrimido[4,5-b]indole 4-amino-5-butyl-9-β-D-ribofuranosylpyrimido[4,5-b]indole 1H-Indole, 6-fluoro-1-beta-D-ribofuranosyl- [4-Acetyloxy-2-(hydroxymethyl)-5-indol-1-yloxolan-3-yl] acetate 4-amino-6-benzofuran-2-yl-9-β-D-ribofuranosylpyrimido[4,5-b]indole 5,6-dichloro-2-bromo-3-formyl-1-(5-O-acetyl-β-D-ribofuranosyl)indole 2-bromo-5,6-dichloro-1-(2,3-O-isopropylidene-β-D-ribofuranosyl)indole 2-bromo-1-(5-O-tert-butyldimethylsilyl-2,3-O-isopropylidene-β-D-ribofuranosyl)-5,6-dichloroindole methyl 2,5,6-trichloro-1-(β-D-ribofuranosyl) indole-3-formimidate 4-(furan-2-yl)-9-β-D-ribofuranosyl-9H-pyrimido[4,5-b]indole 3-[1-[(2R,3R,4R,5R)-3,4-bis(phenylmethoxy)-5-(phenylmethoxymethyl)oxolan-2-yl]-6-phenylmethoxyindol-3-yl]-4-(1H-indol-3-yl)-1-methylpyrrole-2,5-dione tert-butyl 3-[4-[1-[(2R,3R,4R,5R)-3,4-bis(phenylmethoxy)-5-(phenylmethoxymethyl)oxolan-2-yl]-6-phenylmethoxyindol-3-yl]-1-methyl-2,5-dioxopyrrol-3-yl]indole-1-carboxylate 14-(β-D-ribofuranosyl)-naphtho[2,1-α]pyrrolo[3,4-c] carbazole-5,7 (6H,12H)-dione 4-amino-5-phenyl-9-β-D-ribofuranosylpyrimido[4,5-b]indole 4-amino-5-chloro-9-β-D-ribofuranosylpyrimido[4,5-b]indole 4-amino-5-thiophen-3-yl-9-β-D-ribofuranosylpyrimido[4,5-b]indole 4-Amino-6-phenyl-9-β-D-ribofuranosylpyrimido[4,5-b]indole 1-(β-D-ribofuranosyl)indol-3-acetic acid ethyl 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)indol-3-acetate methyl 1-(β-D-ribofuranosyl)indol-3-acetate 1'-deoxy-1'-(6-fluoroindolyl)-β-D-ribofuranose 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1H-indole 1-(2'-O-methyl-β-D-ribofuranosyl)-5-nitroindole 4-amino-6-thiophen-2-yl-9-β-D-ribofuranosylpyrimido[4,5-b]indole 2,5,6-trichloro-1-(2,3-O-isopropylidene-β-D-ribofuranosyl)indole-3-carboxamide 2,5,6-trichloro-1-(2,3-O-isopropylidene-5-O-p-toluenesulfonyl-β-D-ribofuranosyl)indole 1'-deoxy-1'-(5-fluoroindolyl)-β-D-ribofuranose 3-(3-thienyl)-2,5,6-trichloro-1-(2,3-O-isopropylidene-5-O-methoxymethyl-β-D-ribofuranosyl)indole 3-(2-furyl)-2,5,6-trichloro-1-(2,3-O-isopropylidene-5-O-methoxymethyl-β-D-ribofuranosyl)indole 2,5,6-trichloro-3-iodo-1-(β-D-ribofuranosyl)indole β-indolyl-5'-O-(N-salicylsulfamoyl)ribose 3-formyl-2,5,6-trichloro-1-(2,3-O-isopropylidene-β-D-ribofuranosyl)indole 3-formyl-2,5,6-trichloro-1-(2,3-O-isopropylidene-5-O-methoxycarbonyl-β-D-ribofuranosyl)indole 3-cyano-2,5,6-trichloro-1-(2,3-O-isopropylidene-β-D-ribofuranosyl)indole 2,5,6-trichloro-3-propionyl-1-(5-O-acetyl-β-D-ribofuranosyl)indole 3-formyl-2,5,6-trichloro-1-(2,3-O-isopropylidene-5-O-butyryl-β-D-ribofuranosyl)indole 2,5,6-trichloro-3-cyano-1-(β-D-ribofuranosyl)indole 2,5,6-trichloro-3-cyano-1-(5-O-acetyl-β-D-ribofuranosyl)indole